Press Releases

Date Title
02/12/20
Summary ToggleT2 Biosystems to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020 Printer Friendly Version LEXINGTON, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020.
02/04/20
Summary ToggleT2 Biosystems Announces Participation at Clinical Conferences in February Printer Friendly Version Company will highlight need for rapid detection of sepsis-causing pathogens LEXINGTON, Mass. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company’s participation in two conferences in
01/17/20
Summary ToggleT2 Biosystems Reports Granting of Inducement Award Printer Friendly Version LEXINGTON, Mass. , Jan. 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sperzel ,
01/13/20
Summary ToggleT2 Biosystems Promotes Tony Pare to Chief Commercial Officer Printer Friendly Version LEXINGTON, Mass. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel , has promoted Tony Pare to the newly
01/09/20
Summary ToggleT2 Biosystems Announces Preliminary Fourth Quarter 2019 Financial Results Printer Friendly Version Enters Exclusive Distribution Agreement to Expand Sales in Israel LEXINGTON, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and
01/09/20
Summary ToggleT2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer Printer Friendly Version LEXINGTON, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperzel as